How Genentech Created Antibodies to Target Prostate Cancer Cells

A patent describing specific antibodies that latch onto and kill cancer cells expressing the PSCA protein, effectively turning the body's immune-targeting tools into cancer-fighting weapons.

What it covers

This patent covers specific monoclonal antibodies designed to bind to a protein called PSCA, which is found on the surface of certain cancer cells, particularly in the prostate. When these antibodies attach to the PSCA protein, they are internalized by the cell, meaning the cell pulls the antibody inside itself. This mechanism is crucial because it allows the antibody to deliver a toxic payload directly into the cancer cell. The patent specifically claims antibodies produced by six distinct hybridoma cell lines, which are laboratory-grown cells used to mass-produce these precise antibodies.

What it doesn't cover

• —Does not cover antibodies that bind to proteins other than PSCA.
• —Does not cover antibodies that do not internalize into the cell upon binding.
• —Does not cover general methods of cancer treatment that do not use these specific hybridoma-derived antibodies.
• —Does not cover the PSCA protein itself, only the antibodies that target it.

The clever bit

The innovation lies in the discovery that these specific antibodies act like a Trojan horse, forcing the cancer cell to ingest the antibody-drug complex, which then triggers the cell's destruction from the inside.

Why it matters

This patent represents a foundational step in the development of antibody-drug conjugates (ADCs). By identifying a way to force cancer cells to internalize a therapeutic agent, Genentech helped pave the way for targeted cancer therapies that minimize damage to healthy tissue compared to traditional chemotherapy.

Real-world examples

• 1.Targeted prostate cancer immunotherapy research
• 2.Antibody-drug conjugate development pipelines
• 3.Oncology clinical trials focusing on PSCA expression